---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292803852.md"
description: "Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164."
datetime: "2026-07-15T17:49:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292803852.md)
  - [en](https://longbridge.com/en/news/292803852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292803852.md)
---

# 

Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164.

### Related Stocks

- [MANE.US](https://longbridge.com/en/quote/MANE.US.md)

## Related News & Research

- [Buy Rating Reaffirmed on Strong VDPHL01 Data and Catalyst-Rich Roadmap; Price Target Maintained at $164](https://longbridge.com/en/news/295697879.md)
- [Veradermics CEO Reid Alexander Waldman disposes of common shares worth $7.24 million](https://longbridge.com/en/news/296284595.md)
- [Veradermics director John W. Childs disposes of USD 10.18 million in common shares](https://longbridge.com/en/news/295981158.md)
- [Veradermics to discuss Phase 2 results for oral minoxidil hair-loss drug VDPHL01 on July 15 webcast](https://longbridge.com/en/news/292682761.md)
- [Yalla’s Bet On New Mid-And Hardcore Gaming Titles Pays Off](https://longbridge.com/en/news/296504966.md)